Verorab(R) Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Rabies vaccine (Primary) ; Rabies immune globulin
- Indications Rabies
- Focus Registrational; Therapeutic Use
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Dec 2017 to 30 Oct 2018.
- 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Oct 2018.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.